EDSA SEC Filings: 8-K, 10-Q, S-3 & 424B – Edesa Biotech

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Feb 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Dec 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 8, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWEdesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan

Nov 9, 2026

8-K

Edesa Biotech Announces Base Salary Increases for Top Executives

Oct 23, 2026

8-K

Edesa Biotech Receives FDA Clearance for Phase 2 IND Application for EB06 in Vitiligo

Oct 15, 2026

8-K

Edesa Biotech Announces Pricing of $23.1 Million Underwritten Offering

Aug 20, 2026

8-K

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results and Operational Updates

Aug 13, 2026

8-K

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares

Jun 11, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Aug 20, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Guggenheim Securities

Aug 19, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 729,241

Jul 13, 2026

424B5

December 2025 ATM | Offering amount: $2,262,508 | Amount sold to date: $4,162,030 | Float: 7,034,167

Dec 12, 2025

424B5

September 2025 ATM | Offering amount: $4,006,544 | Amount sold to date: $837,134 | Float: 5,743,492

Sep 9, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Mar 11, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

Jul 2, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Jun 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 29, 2026

S-3

July 2025 SHELF | Float: 5,738,344 | Amount sold to date: $837,134 EFFECTIVE, DATED 2025-09-09

Jul 25, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 28, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

Mar 4, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 3, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 4, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 4, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 5, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 5, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Nijhawan Pardeep (Reporting)

Nov 5, 2026

SCHEDULE 13G/A

INTEGRATED CORE STRATEGIES (US) LLC (Filed by)

Nov 4, 2026

Nijhawan Pardeep (Reporting)

Oct 29, 2026

Nijhawan Pardeep (Reporting)

Oct 6, 2026

Nijhawan Pardeep (Reporting)

Sep 1, 2026

SCHEDULE 13G

Stonepine Capital Management, LLC (Filed by)

Aug 26, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 14, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 10, 2025

CORRESP

Form CORRESP - Correspondence

Sep 5, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 30, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 12, 2025

CORRESP

Form CORRESP - Correspondence

Mar 7, 2025

Edesa Biotech, Inc. EDSA · SEC Filings